메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
저널정보
한국분자세포생물학회 Molecules and Cells Molecules and Cells 제33권 제2호
발행연도
2012.1
수록면
173 - 181 (9page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Rosiglitazone has the potential to activate peroxisome proliferator-activated receptor- (PPAR), which in turn can affect bone formation and resorption. However, the mecha-nisms by which rosiglitazone regulates osteoclastic or osteoblastic differentiation are not fully understood. This study examines how rosiglitazone affects osteoclast for-mation, bone resorption and osteoblast differentiation from mouse bone marrow. Rosiglitazone treatment not only inhibited the formation of tartrate-resistant acid phosphatase-positive cells, but also prevented pit forma-tion by bone marrow cells in a dose- and time-dependent manner. Rosiglitazone also suppressed the receptor acti-vator of nuclear factor (NF)-B ligand (RANKL) receptor (RANK) expression but increased PPAR2 expression in the cells. In addition, rosiglitazone diminished RANKL-induced activation of NF-B-DNA binding by blocking IB phosphorylation. Furthermore, it reduced collagen and osteocalcin levels to nearly zero and prevented mRNA expression of osteoblast-specific proteins including runt-related tran-scription factor-2, osteocalcin, and type I colla-gen. How-ever, mRNA levels of adipocyte-specific marker, aP2, were markedly increased in the cells co-incubated with rosigli-tazone. These results suggest that PPAR acti-vation by rosiglitazone inhibits osteoblast differentiation with in-creased adipogenesis in bone marrow cells and also may prevent osteoclast formation and bone resorp-tion in the cells.

목차

등록된 정보가 없습니다.

참고문헌 (22)

참고문헌 신청

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0